Cardiac Amyloidosis: ATTR vs AL Diagnosis, PYP Scintigraphy, Genetic Testing, and Stage-Based Therapy

Cardiac Amyloidosis: ATTR vs AL Diagnosis, PYP Scintigraphy, Genetic Testing, and Stage-Based Therapy

Comprehensive evidence-based guideline for diagnosis and management of cardiac amyloidosis in adults — from clinical clues and red flags through PYP scintigraphy, mandatory monoclonal protein workup, ATTR genotyping, biopsy indications, and stage-specific disease-modifying therapy with tafamidis, patisiran, and AL chemotherapy.

Author: gomdori, MDCategory: CardiologyUpdated: May 2026

Executive Summary

Cardiac amyloidosis is an under-recognized cause of HFpEF, restrictive cardiomyopathy, and unexplained left ventricular hypertrophy that is now treatable when diagnosed early. The two clinically dominant subtypes are ATTR amyloidosis (transthyretin — wild-type ATTRwt in elderly males or hereditary ATTRv) and AL amyloidosis (immunoglobulin light chain from a plasma cell dyscrasia). Diagnosis follows a fixed sequence: (1) recognize red flags — discordant LV wall thickness greater than ECG voltage, low-flow low-gradient aortic stenosis, bilateral carpal tunnel syndrome years before HF, lumbar spinal stenosis, autonomic neuropathy, polyneuropathy, biceps tendon rupture; (2) mandatory monoclonal protein workup with serum and urine immunofixation plus serum free light chain ratio — abnormal results require hematology referral and tissue biopsy; (3) if monoclonal workup is negative, technetium-99m PYP (or DPD/HMDP) bone scintigraphy with Perugini grade 2 or 3 myocardial uptake is diagnostic of ATTR cardiac amyloidosis without biopsy; (4) ATTR diagnosis mandates TTR gene sequencing to distinguish wild-type from variant disease (e.g., V122I in 3–4% of African ancestry) and screen at-risk relatives. Treatment is subtype-specific: AL requires urgent hematologic therapy (daratumumab–CyBorD induction, autologous stem cell transplant in eligible patients), ATTR is managed with the TTR stabilizer tafamidis 61 mg PO daily (ATTR-ACT trial — 30% mortality reduction over 30 months) or TTR gene silencers (patisiran, vutrisiran, eplontersen) for ATTRv with polyneuropathy. Heart failure management requires careful diuresis, avoidance of beta-blockers and ACEi/ARB if hypotensive, and cautious anticoagulation given the high stroke risk despite sinus rhythm. Mayo and NAC staging predicts survival and guides intensity of therapy.

13–17%ATTR prevalence in HFpEF age >60
6 moUntreated AL stage IV survival
30%Tafamidis mortality reduction (ATTR-ACT)
3–4%V122I TTR variant in African ancestry

1. Subtypes, Pathophysiology, and Epidemiology

The Two Clinically Dominant Subtypes

Cardiac amyloidosis results from extracellular deposition of misfolded protein fibrils that disrupt myocardial architecture, increase stiffness, and impair both systolic and diastolic function. Although more than 30 amyloidogenic precursor proteins exist, two account for nearly all cardiac cases:

  • ATTR amyloidosis — transthyretin (formerly prealbumin), produced primarily by the liver as a tetramer that transports thyroxine and retinol-binding protein. Misfolding and dissociation generate amyloidogenic monomers. Two forms:
    • ATTRwt (wild-type) — formerly “senile cardiac amyloidosis”; idiopathic age-related misfolding of normal TTR. Predominant in men over 65; mean age at diagnosis 75. Estimated 13–17% prevalence in HFpEF over 60, and 16% in low-flow low-gradient aortic stenosis.
    • ATTRv (variant or hereditary) — autosomal dominant TTR mutations. Over 130 known pathogenic variants. Most common in Western practice: V122I (Val122Ile, present in 3–4% of African ancestry, manifests after age 60 with cardiomyopathy); T60A (Irish/UK lineage); V30M (Portuguese/Swedish/Japanese, classic familial amyloid polyneuropathy).
  • AL amyloidosis — immunoglobulin light chain (lambda more often than kappa) produced by an underlying plasma cell dyscrasia (often small, often without overt myeloma). Median age 65 but ranges 40–80. AL is rapidly fatal without treatment; cardiac involvement in 50–75% of AL cases drives prognosis.

Less Common Subtypes

  • AA amyloidosis — secondary to chronic inflammation (RA, IBD, FMF, chronic infection); rarely cardiac dominant
  • AApoAI / AApoAII — apolipoprotein variants, very rare
  • Localized cardiac amyloidosis — atrial natriuretic peptide deposition in atria of elderly; clinical significance limited

Mechanism of Myocardial Dysfunction

Amyloid fibrils accumulate between cardiomyocytes, in the interstitium, and around vessels, producing a thick, stiff, non-compliant ventricle with preserved or near-preserved ejection fraction (HFpEF phenotype) but markedly impaired longitudinal strain, restrictive filling, and biatrial enlargement. Coronary microvascular involvement causes angina without obstructive epicardial disease. AL light chains additionally exert direct toxicity on cardiomyocytes (oxidative stress, lysosomal dysfunction), explaining why AL has more rapid hemodynamic deterioration and worse prognosis stage-for-stage than ATTR despite less amyloid burden by volume. Autonomic and somatic nerve infiltration produces orthostatic hypotension, gastroparesis, erectile dysfunction, and small-fiber neuropathy.

At-Risk Populations and Screening Triggers

PhenotypeEstimated amyloidosis prevalenceRecommended workup
HFpEF age >60 with LV wall >12 mm13–17%Monoclonal workup + PYP scan if monoclonal negative
Low-flow, low-gradient aortic stenosis~16%Same — esp. before TAVR planning
Unexplained LVH age >65 (no HTN history)20–30%Same; consider HCM gene panel if also young
Bilateral carpal tunnel + HF or LVH~50%Mandatory amyloid workup
Lumbar spinal stenosis + HF or LVH30–40%Mandatory amyloid workup
Bicep tendon rupture + cardiac symptomsIncreasedConsider amyloid workup
Family history of TTR amyloidosis50% (if first-degree relative carrier)Genetic counseling + TTR sequencing

2. Clinical Red Flags and Initial Imaging

Cardiac Red Flags

  • HFpEF in a patient without typical risk factors (especially elderly males)
  • LV wall thickness greater than 12 mm with low ECG voltage (Sokolow-Lyon less than 1.5 mV) — voltage-mass discordance is the single most useful red flag
  • Pseudoinfarct pattern on ECG (Q waves in V1–V3 without coronary occlusion)
  • Conduction disease — first-degree AV block, bifascicular block, complete heart block
  • Atrial fibrillation in the absence of valvular disease, especially with biatrial enlargement
  • Low-flow low-gradient aortic stenosis with paradoxically preserved EF
  • Restrictive filling pattern on echo (E/A >2, deceleration time <160 ms)
  • Apical sparing pattern of longitudinal strain (“cherry on top”) — relative apex preservation with severe basal/mid-ventricular dysfunction
  • Pericardial effusion (small to moderate) without clear etiology
  • Disproportionate elevation of NT-proBNP for symptom severity
  • Persistent troponin elevation without acute coronary syndrome

Extra-Cardiac Red Flags

  • Carpal tunnel syndrome — bilateral, frequently 5–10 years before cardiac symptoms
  • Lumbar spinal stenosis
  • Spontaneous biceps tendon rupture (Popeye sign)
  • Polyneuropathy (length-dependent, sensory predominant)
  • Autonomic dysfunction — orthostatic hypotension, erectile dysfunction, gastroparesis
  • Macroglossia (AL only — pathognomonic when present, but uncommon)
  • Periorbital purpura — “raccoon eyes” (AL only)
  • Nephrotic-range proteinuria (AL more often than ATTR)
  • Hepatomegaly with elevated alkaline phosphatase, no hepatic mass

ECG Voltage-Mass Discordance

Although classically described, low ECG voltage occurs in only 30–40% of cardiac amyloidosis. The more sensitive finding is voltage that is inappropriately low for the degree of LVH. Calculate the ratio of Sokolow-Lyon voltage (S in V1 + R in V5 or V6) to LV mass index — values below 1.5 mV with septal thickness >12 mm strongly suggest infiltrative disease. Pseudoinfarct Q waves in anterior precordial leads occur in 50% and result from amyloid-replaced myocardium rather than infarction.

Echocardiography

FindingSignificanceLimitation
LV wall thickness >12 mm (often >15 mm)Suggests infiltrative cardiomyopathyOverlaps with HCM, hypertensive heart disease
Granular sparkling myocardial echotextureClassic but operator-dependent and modern transducers reduce sensitivityNow considered nonspecific
Biatrial enlargement disproportionate to AFRestrictive physiologyAlso seen in chronic AF, MS
RV wall thickening >6 mmSuggests amyloidosis (HCM rarely affects RV)Useful discriminator
Apical sparing on global longitudinal strainRelative apex strain preservation; bullseye plot diagnosticBest discriminator from other LVH causes; operator-dependent
Restrictive mitral inflow (E/A >2)Late-stage findingInsensitive early
Low LV outflow tract velocity time integralLow-flow stateMay coexist with low-gradient AS
Small to moderate pericardial effusionCommon but nonspecificTamponade rare

Cardiac MRI

Cardiac MRI provides high sensitivity but cannot distinguish amyloid subtype. Characteristic findings:

  • Diffuse subendocardial late gadolinium enhancement (LGE) not following coronary territory — pathognomonic
  • Difficulty nulling the myocardium on look-locker sequences (myocardium nulls before or simultaneously with blood pool)
  • Markedly elevated extracellular volume (ECV) — values >0.40 highly suggestive (normal <0.30)
  • Native T1 mapping >1100 ms (vendor-dependent thresholds)
  • Atrial wall LGE in advanced disease

3. Mandatory Monoclonal Workup First

The Diagnostic Sequence is Fixed

Critical principle: monoclonal protein workup MUST precede PYP scan

PYP scintigraphy can be falsely positive in AL amyloidosis (5–20% of AL cases show some myocardial uptake) and a positive PYP scan in a patient with undiagnosed AL can lead to fatal misdiagnosis as ATTR with delayed AL treatment. AL amyloidosis is far more aggressive, with median survival of 6 months for stage IV without treatment. Always exclude AL before declaring ATTR.

Three-Test Monoclonal Workup

TestWhat it detectsSensitivity for AL
Serum immunofixation electrophoresis (SIFE)Monoclonal IgG, IgA, IgM heavy chain or free light chain~75%
Urine immunofixation electrophoresis (UIFE) (24-hour collection or random with creatinine)Bence Jones protein~70%
Serum free light chain (sFLC) assay with kappa/lambda ratioFree light chain excess; abnormal ratio <0.26 or >1.65 (renal-adjusted: <0.37 or >3.1 if eGFR reduced)~95%

The combination of all three tests has greater than 99% sensitivity for plasma cell dyscrasia. Any positive result mandates hematology referral and tissue biopsy; do not proceed to PYP without a complete monoclonal workup.

Hematology Referral and Bone Marrow Biopsy

An abnormal monoclonal workup requires:

  • Hematology consultation
  • Bone marrow biopsy with aspirate, flow cytometry, and Congo red staining
  • Skeletal survey or PET/CT for myeloma evaluation
  • Beta-2 microglobulin, calcium, creatinine, LDH
  • If amyloid is found in bone marrow or another biopsy site, mass spectrometry (laser capture microdissection with liquid chromatography-tandem MS — LC-MS/MS) confirms the precursor protein (AL kappa, AL lambda, or ATTR contamination)

What if Monoclonal Workup is Equivocal?

Monoclonal gammopathy of undetermined significance (MGUS) is present in 3–5% of adults over 50 and 10% over 75 — coincidental MGUS in a patient with cardiac amyloidosis does not exclude ATTR. The discriminator is tissue typing by mass spectrometry. If sFLC ratio is borderline abnormal but no M-spike on SIFE/UIFE and clinical pattern strongly suggests ATTR (e.g., elderly male, bilateral carpal tunnel, V122I ethnic background), proceed with PYP scan but pursue tissue biopsy if PYP is grade 1 or equivocal. Hematology should always be involved when monoclonal workup is positive.

Cardiac Amyloidosis — Procedure Steps Surgical stepper: Cardiac Amyloidosis — Procedure Steps Cardiac Amyloidosis — Procedure Steps 1 AL: chemotherapy CyBorD (cyclophosphamide + bortezomib + dexamethasone) + ASCT eligibility; daratumumab-CyBorD newer 2 ATTR: tafamidis Tafamidis 80mg PO daily (Vyndamax 61mg = bioequivalent) — TTR stabilizer; reduces 3 ATTR: gene silencing Patisiran 0.3 mg/kg IV q3wk (siRNA; APOLLO trial) OR inotersen 284mg SC weekly (antisense oligo) — f 4 Heart failure mgt Diuretics (loop ± spironolactone) — careful titration; AVOID beta-blockers, ACE-I, ARBs 5 Arrhythmia + AC AF common (40-70%): rate control with cautious BB/CCB; AC for all AF (low CHA2DS2-VASc threshold); a 6 Heart transplant Selected AL patients post-chemo with no extracardiac amyloid; ATTR-wt: less commonly;
Cardiac Amyloidosis — Procedure Steps

4. PYP Scintigraphy and Tissue Biopsy

Technetium-99m PYP/DPD/HMDP Bone Scintigraphy

Bone-avid radiotracers (99mTc-pyrophosphate in the US, 99mTc-DPD or HMDP in Europe) bind to ATTR amyloid fibrils with high specificity, producing distinctive myocardial uptake. The Perugini grading system is used:

Perugini gradeVisual finding (3-hour planar)Interpretation
Grade 0No myocardial uptake; ribs visibleATTR very unlikely (sensitivity ~99% if grade 0)
Grade 1Myocardial uptake less than rib uptakeEquivocal — biopsy required
Grade 2Myocardial uptake equal to rib uptakeDiagnostic of ATTR (specificity >95% IF monoclonal workup negative)
Grade 3Myocardial uptake greater than rib uptakeDiagnostic of ATTR (specificity >95% IF monoclonal workup negative)

SUV Ratio (Quantitative)

SPECT/CT permits quantitative analysis with the heart-to-contralateral-lung (H/CL) ratio measured on planar imaging at 1 hour:

  • H/CL >1.5 at 1 hour highly suggestive of ATTR
  • H/CL >1.0 at 3 hours diagnostic when paired with grade 2–3 visual uptake
  • SPECT confirms myocardial (rather than blood pool) localization — essential because planar grade 2 uptake from blood pool can be misclassified as myocardial

Non-Biopsy Diagnostic Pathway

The Gillmore criteria allow non-invasive diagnosis of ATTR cardiac amyloidosis when ALL of the following are met:

  • Heart failure or cardiac findings consistent with amyloidosis
  • Echocardiographic or CMR findings consistent with amyloidosis
  • Perugini grade 2 or 3 myocardial uptake on PYP/DPD/HMDP scan
  • Negative serum and urine immunofixation AND normal serum free light chain ratio

If all four criteria are met, the specificity for ATTR exceeds 99% and biopsy is not required. If any criterion is not met, tissue biopsy is mandatory.

Tissue Biopsy Indications

ScenarioRequired biopsyRationale
Any positive monoclonal workupBone marrow + abdominal fat pad (or affected organ); endomyocardial if extracardiac negativeConfirm AL and identify subtype
PYP grade 1 or equivocalEndomyocardial biopsyInsufficient for non-invasive diagnosis
PYP grade 0 with strong clinical suspicionEndomyocardial biopsyRare AL or non-TTR amyloid possible
Clinical-imaging discordanceEndomyocardial biopsyRule out other infiltrative diseases

Histology and Subtyping

Congo red staining shows apple-green birefringence under polarized light — this confirms amyloid but does not identify the precursor protein. Mass spectrometry (LC-MS/MS on laser-capture-microdissected Congo-red-positive tissue) identifies the exact protein and is now the gold standard for amyloid typing. Immunohistochemistry with anti-TTR, anti-kappa, anti-lambda, and anti-AA antibodies may be used in centers without mass spectrometry but is less reliable.

TTR Gene Sequencing After ATTR Diagnosis

Every patient with confirmed ATTR cardiac amyloidosis requires TTR sequencing — even if “obviously” wild-type by age and ethnicity. Approximately 5–10% of patients clinically suspected of ATTRwt actually carry a variant. Confirmation of:

  • ATTRwt — no further genetic action; family screening unnecessary
  • ATTRv — first-degree relatives offered genetic counseling and TTR sequencing; carrier siblings/children may benefit from baseline cardiac and neurologic evaluation, with periodic surveillance for disease onset
Cardiac Amyloidosis Diagnostic Algorithm Flowchart from clinical suspicion through monoclonal workup to PYP scintigraphy and biopsy decision tree Clinical suspicion + echo/CMR Red flags, voltage-mass discord, apical sparing Monoclonal workup FIRST SIFE + UIFE + serum free light chain Positive: Heme + tissue Bx Mass spec to confirm AL vs ATTR Negative: PYP/DPD scan Perugini grade + H/CL ratio Grade 2-3 = ATTR confirmed Then TTR gene sequencing AL confirmed = urgent CyBorD Add daratumumab; ASCT if eligible Initiate disease-modifying therapy + HF management
Figure 1. Cardiac amyloidosis diagnostic algorithm — monoclonal workup precedes PYP scintigraphy

5. ATTR Disease-Modifying Therapy

Treatment Selection by Subtype and Phenotype

DiagnosisFirst-line disease-modifying therapyMechanism
ATTRwt cardiac amyloidosisTafamidis 61 mg PO daily (or acoramidis 800 mg BID)TTR tetramer stabilizer — prevents dissociation
ATTRv with cardiomyopathy (no/mild PN)Tafamidis 61 mg PO daily OR vutrisiran 25 mg SC q3moStabilizer or hepatic TTR mRNA silencer
ATTRv with polyneuropathy (with/without CM)Patisiran 0.3 mg/kg IV q3wk OR vutrisiran 25 mg SC q3mo OR eplontersen 45 mg SC monthlysiRNA or ASO — silence TTR production
AL cardiac amyloidosisDaratumumab + CyBorD (cyclophosphamide-bortezomib-dexamethasone) inductionSuppress plasma cell light chain production; ASCT in eligible patients

Tafamidis — ATTR-ACT Pivotal Trial

The ATTR-ACT trial (NEJM 2018) randomized 441 patients with ATTR cardiomyopathy to tafamidis (80 mg or 20 mg) vs placebo for 30 months. Pooled tafamidis reduced all-cause mortality by 30% (HR 0.70) and cardiovascular hospitalizations by 32%. Benefits emerged at approximately 18 months and increased over time. Open-label extension confirms continued separation of survival curves through 60 months. The 80 mg dose (now reformulated as tafamidis meglumine 61 mg once daily, equivalent to 80 mg tafamidis acid) is the FDA-approved dose. Tafamidis is well tolerated; no significant adverse events vs placebo. Cost is the principal limitation (US list price ~$200,000/year).

Acoramidis (Newer TTR Stabilizer)

Acoramidis is a near-complete TTR stabilizer that achieved a clinically and statistically significant reduction in the composite of all-cause mortality and cardiovascular hospitalization at 30 months in the ATTRibute-CM trial. Dose: 800 mg PO BID. FDA approved 2024. Direct comparison with tafamidis lacking; both are reasonable first-line stabilizers.

TTR Silencers — Indications and Use

DrugMechanismDose / routeApproved indication
PatisiransiRNA in lipid nanoparticle; reduces hepatic TTR ~80%0.3 mg/kg IV every 3 weeks; premedication required (steroid + antihistamine + acetaminophen)ATTRv polyneuropathy; cardiac use under investigation
VutrisiranNext-generation siRNA, GalNAc-conjugated, longer-acting25 mg SC every 3 monthsATTRv polyneuropathy; HELIOS-B showed cardiac benefit including in ATTRwt
EplontersenAntisense oligonucleotide GalNAc-conjugated45 mg SC monthly self-administeredATTRv polyneuropathy; CARDIO-TTRansform pending

NAC Staging and Prognosis

The UK National Amyloidosis Centre (NAC) staging system stratifies ATTR cardiac amyloidosis prognosis using two biomarkers:

  • Stage I — NT-proBNP ≤3000 ng/L AND eGFR ≥45 mL/min/1.73m². Median survival ~70 months.
  • Stage II — NT-proBNP >3000 OR eGFR <45 (but not both). Median survival ~47 months.
  • Stage III — NT-proBNP >3000 AND eGFR <45. Median survival ~24 months.

Tafamidis benefit is preserved across NAC stages but advanced stage (NYHA IV, NAC III with severe disease) shows attenuated benefit; some clinicians defer initiation in moribund patients given cost and slow onset of action.

AL-Specific Considerations Before ATTR Therapy

If AL is identified, ATTR-directed therapy (tafamidis, acoramidis, TTR silencers) is contraindicated and inappropriate. AL must be treated with hematologic regimens (next section).

Practice Insights: Cardiac Amyloidosis — AL Exclusion FIRST, PYP Scintigraphy for ATTR, and Tafamidis Era

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A PYP scan ordered before light chains are excluded can label AL amyloidosis as ATTR and cost the patient the only treatment that works — (1) AL amyloidosis must be EXCLUDED FIRST with immunofixation + free light chains before PYP scintigraphy (PYP can be falsely positive in AL); (2) PYP scintigraphy is non-invasive diagnostic for ATTR when AL excluded — replacing biopsy for most cases; (3) tafamidis 61 mg daily for ATTR-CM has transformed prognosis per ATTR-ACT NEJM 2018 — initiated in any Stage I-II patient. The “biopsy required for all amyloid” era has ended.

AL exclusion FIRST: serum + urine immunofixation + free light chains

Before any PYP scintigraphy, screen for AL amyloidosis: serum AND urine immunofixation electrophoresis (SIFE + UIFE) + serum free light chains (kappa + lambda + K/L ratio). The reason: PYP scintigraphy can be falsely positive in AL amyloidosis, leading to missed AL diagnosis and inappropriate treatment. If AL screen positive (abnormal IFE, abnormal K/L ratio > 1.65 or < 0.26), proceed to hematology workup (bone marrow biopsy, serum/urine M-spike, Congo red staining of tissue). AL amyloidosis is an oncology emergency — treat the underlying plasma cell dyscrasia with daratumumab-based regimens (Dara-CyBorD per ANDROMEDA NEJM 2021). If AL screen NEGATIVE, proceed to PYP scintigraphy.

PYP scintigraphy: non-invasive diagnostic for ATTR (95% specificity if AL excluded)

99mTc-pyrophosphate (PYP) scintigraphy is the non-invasive diagnostic gold standard for ATTR cardiac amyloidosis when AL has been excluded. Grading: Grade 0 (negative, no uptake), Grade 1 (equivocal, mild uptake less than bone), Grade 2 (moderate uptake equal to bone), Grade 3 (intense uptake greater than bone). Quantitative heart/contralateral lung ratio (H/CL) ≥ 1.5 at 1 hour confirms diagnosis. Grade 2-3 PYP with negative AL screen = ATTR cardiac amyloidosis with 95% specificity — biopsy no longer needed for most cases. Endomyocardial biopsy reserved for ambiguous PYP (Grade 1), positive AL screen with negative bone marrow, atypical features.

Genetic testing for hATTR after ATTR confirmed

After ATTR confirmed by PYP, send genetic testing for hereditary ATTR (hATTR) mutations. Common variants: Val122Ile in African-Americans (3-4% population prevalence — important to test, often missed!), Val30Met (endemic in Portugal, Sweden, Japan), T60A (Ireland). Wild-type ATTR (wtATTR — formerly “senile cardiac amyloidosis”) is the most common in elderly white men — no mutation, but treatment same as hATTR for cardiomyopathy. Mutation identification has 2 implications: (1) drives screening of first-degree relatives (autosomal dominant inheritance); (2) opens treatment options including patisiran/inotersen for hATTR-PN (polyneuropathy).

Tafamidis 61 mg daily for ATTR-CM — Mayo Stage-driven initiation

Tafamidis (Vyndaqel 80 mg or Vyndamax 61 mg PO daily) is a TTR kinetic stabilizer with STRONG evidence from ATTR-ACT NEJM 2018: 30% reduction in all-cause mortality + cardiovascular hospitalization at 30 months in wtATTR/hATTR-CM. Experienced clinicians initiate tafamidis in any Mayo Stage I-II patient with good functional status. Stage III patients (NT-proBNP > 3000 + troponin T > 0.05) have lower response rates but still considered. Acoramidis (Attruby, FDA 2024) is alternative per ATTRibute-CM. Vutrisiran (Amvuttra, FDA 2024 for ATTR-CM per HELIOS-B) is SC q 3 months siRNA — important option for tafamidis nonresponders. Avoid: ACE/ARB, beta-blockers (autonomic insufficiency, hypotension in amyloidosis); use loop diuretics carefully (sensitive to depletion); anticoagulation for AF or LV thrombus (intracardiac thrombus risk despite preserved EF).

Anonymized Case: wtATTR-CM with Bilateral Carpal Tunnel Hint → Tafamidis Treatment

A man in his late seventies (no diabetes, mild HTN on amlodipine) presented with progressive exertional dyspnea over 6 months, fatigue, and bilateral lower-extremity edema. Past medical history significant for bilateral carpal tunnel syndrome treated surgically 5 years prior (RED FLAG — bilateral CTS often precedes ATTR cardiac symptoms by years). Vital signs: HR 78, BP 118/74 (relatively low for prior HTN — suggesting reduced cardiac output), RR 18. Exam: bilateral basilar crackles, S4 gallop, mild ankle edema. ECG: low voltage in limb leads despite LV hypertrophy on echo. Echocardiogram: LVEF 55% (preserved); LV wall thickness 14 mm (concentric); apical-sparing global longitudinal strain pattern (“cherry on top” — strongly suggestive of cardiac amyloid); biatrial enlargement; restrictive diastolic dysfunction. Laboratory: NT-proBNP 5,200 pg/mL (very elevated for preserved EF), troponin T 0.08 ng/mL (mildly elevated), Cr 1.1, normal liver function. AL screen FIRST: serum immunofixation negative, urine immunofixation negative, serum free light chains kappa 18, lambda 14, K/L ratio 1.29 (NORMAL — AL excluded). 99mTc-PYP scintigraphy: Grade 3 uptake, heart/contralateral lung ratio 1.8 at 1 hour — strongly positive for ATTR cardiac amyloidosis. Diagnosis: ATTR-CM with AL excluded. Genetic testing: wtATTR (wild-type, no mutation — family screening not needed). Mayo Stage III (NT-proBNP > 3000 + troponin T > 0.05). Treatment: tafamidis 61 mg PO daily initiated. Loop diuretic furosemide 20 mg daily for fluid management (low dose, careful titration to avoid depletion). Discontinued amlodipine and avoided ACE-I/beta-blocker (autonomic instability risk in cardiac amyloid). 12-month follow-up: NYHA II (improved from III), NT-proBNP decreased to 3,200, no HF hospitalization, sustained on tafamidis. New atrial fibrillation diagnosed on Holter monitor — initiated apixaban 5 mg BID for stroke prevention (intracardiac thrombus risk in amyloid despite preserved EF).

The takeaway: bilateral carpal tunnel syndrome history was the RED FLAG that prompted amyloidosis workup despite “just HFpEF” presentation. AL excluded first (mandatory before PYP). PYP Grade 3 confirmed ATTR non-invasively. Tafamidis improved symptoms and biomarkers within 12 months. Apixaban for AF given thrombus risk in amyloid heart even with preserved EF.

Four Protocol Deviations Seasoned Clinicians Now Default To

  1. AL exclusion FIRST: serum + urine immunofixation + free light chains (K/L ratio). PYP can be falsely positive in AL. If AL screen positive → hematology workup (bone marrow, M-spike, Congo red) + oncology-emergency treatment (Dara-CyBorD per ANDROMEDA). If AL negative → PYP.
  2. PYP scintigraphy Grade 2-3 + AL excluded = ATTR (95% specificity, biopsy avoided). H/CL ratio ≥ 1.5 at 1h confirms. Grade 1 equivocal → consider biopsy. Biopsy reserved for ambiguous PYP, positive AL with negative marrow, atypical features.
  3. Genetic testing after ATTR confirmed. Val122Ile in African-Americans (3-4% prevalence, frequently missed), Val30Met endemic (Portugal/Sweden/Japan), T60A (Ireland), wtATTR (no mutation, elderly white men). Drives family screening for hATTR + opens hATTR-PN treatment options.
  4. Tafamidis 61 mg daily for ATTR-CM at Mayo Stage I-II — initiate promptly. ATTR-ACT NEJM 2018: 30% mortality + HF hospitalization reduction. Acoramidis alternative (ATTRibute-CM, FDA 2024). Vutrisiran for tafamidis nonresponders (HELIOS-B). AVOID ACE/ARB/beta-blockers (autonomic instability). Anticoagulation for AF or LV thrombus despite preserved EF.
Cardiac amyloidosis bedside protocol: AL exclusion + PYP scintigraphy + genetic testing + tafamidis treatment Two-panel diagram showing cardiac amyloidosis diagnostic workflow with AL exclusion preceding PYP and ATTR-CM treatment ladder. Cardiac Amyloidosis: AL Exclusion FIRST + PYP + Tafamidis Panel A: Diagnostic Workflow Step 1: AL exclusion FIRST Serum + urine immunofixation Free light chains (K/L ratio 0.26-1.65 normal) AL positive → hematology workup: Bone marrow biopsy, Congo red, M-spike Treat: Dara-CyBorD (ANDROMEDA NEJM 2021) AL negative → Step 2: PYP scintigraphy 99mTc-PYP grade 0-3 + H/CL ratio ≥ 1.5 at 1h Grade 2-3 = ATTR (95% specificity) Step 3: Genetic testing post-ATTR Val122Ile (African-American 3-4%), V30M, T60A wtATTR (no mutation, elderly males) Panel B: Treatment Ladder Tafamidis 61 mg PO daily: TTR kinetic stabilizer (ATTR-ACT NEJM 2018) 30% mortality + HF hospitalization reduction Mayo Stage I-II preferred initiation Acoramidis (Attruby, FDA 2024): Alternative TTR stabilizer (ATTRibute-CM) 800 mg PO BID Vutrisiran SC q 3 months (FDA 2024): siRNA, HELIOS-B for ATTR-CM Important for tafamidis nonresponders AVOID: ACE/ARB, beta-blockers Autonomic insufficiency + hypotension Use loop diuretic carefully (volume sensitive) Anticoagulation if AF or LV thrombus RED FLAGS: HFpEF + LV wall thickening + low voltage ECG + apical sparing strain + bilateral CTS • Bilateral carpal tunnel syndrome often precedes ATTR cardiac symptoms by 5-10 years — clinical pearl • Mayo ATTR staging: I (NT-proBNP ≤ 3000 + troponin T ≤ 0.05), II (one elevated), III (both elevated)

6. AL Therapy, HF Management, and Special Considerations

AL Amyloidosis — Urgent Hematology Treatment

Treatment intensity depends on Mayo 2012 staging using cardiac biomarkers (NT-proBNP, troponin T or I) and free light chain difference:

Mayo 2012 stageDefinitionMedian OS untreated
Stage I0 of 3 markers above threshold~94 months
Stage II1 marker above~40 months
Stage III2 markers above~14 months
Stage IV3 markers above (NT-proBNP >1800, troponin elevated, dFLC >180)~6 months

Standard induction (ANDROMEDA trial) is daratumumab + cyclophosphamide + bortezomib + dexamethasone (Dara-CyBorD) for 6 cycles. Hematologic complete response (negative immunofixation, normal sFLC ratio) is the goal; achievement predicts cardiac and renal response and improved survival. Autologous stem cell transplant (ASCT) is reserved for younger fit patients (typically <70 years, ECOG 0–2, NT-proBNP <5000, no severe cardiac involvement) — Mayo Clinic transplant eligibility criteria. Cardiac response (NT-proBNP reduction >30% with absolute value <300) is associated with substantial survival benefit.

Heart Failure Management — Unique Principles

Drug classUse in cardiac amyloidosisCaveat
Loop diuretics (furosemide, torsemide)Cornerstone for congestionAggressive titration; orthostasis common from autonomic neuropathy
MRA (spironolactone)Useful for fluid management, low-dose 12.5–25 mgWatch K, especially with ACEi/ARB and CKD
ACEi / ARB / ARNIGenerally poorly toleratedHypotension common; many patients require discontinuation
Beta-blockersAvoid or use very low doseNegative inotropy in restrictive heart with fixed stroke volume causes worsening output and orthostatic hypotension; preserved heart rate is needed for cardiac output
Calcium channel blockers (verapamil, diltiazem)AVOIDBind avidly to amyloid; can precipitate complete heart block and cardiogenic shock
DigoxinAVOIDBinds to amyloid fibrils; toxicity at therapeutic levels
SGLT2 inhibitors (dapagliflozin, empagliflozin)Reasonable in HFpEF/HFrEF, including amyloidosisModest data in amyloidosis; benefit likely class effect for HF

Atrial Fibrillation and Anticoagulation

AF prevalence in cardiac amyloidosis exceeds 50%, and the stroke risk from atrial mechanical dysfunction is high even in sinus rhythm. Thrombus formation in the left atrial appendage occurs in 30% of AF patients with amyloidosis even when therapeutically anticoagulated. Strategy:

  • Anticoagulate any patient with AF or atrial flutter regardless of CHA2DS2-VASc score — apixaban 5 mg BID preferred
  • TEE before cardioversion mandatory regardless of AC duration (high LAA thrombus prevalence)
  • Rate control challenging — beta-blockers and CCBs poorly tolerated; consider amiodarone for both rate and rhythm control
  • Catheter ablation feasible in selected patients but recurrence rate higher than non-amyloid AF
  • Consider oral anticoagulation in advanced cardiac amyloidosis with biatrial enlargement even in sinus rhythm — recommendations are evolving

Conduction Disease and Devices

Conduction disease (first-degree AV block, bifascicular block, complete heart block) is common and progressive. Pacemaker indications follow standard guidelines but the threshold for prophylactic device placement is lower in advanced amyloidosis. Implantable cardioverter-defibrillators are controversial — sudden cardiac death is more often pulseless electrical activity (electromechanical dissociation) than ventricular tachyarrhythmia, and ICD shocks may not improve survival; consider on case-by-case basis.

Aortic Stenosis Coexistence and TAVR

Approximately 16% of low-flow low-gradient aortic stenosis cases harbor cardiac amyloidosis. Patients with both diseases benefit from TAVR but have lower survival than AS-only patients. Screening TTR-PYP scan should be considered in all elderly patients with low-flow low-gradient AS before structural valve intervention.

Cardiac Transplantation

Heart transplantation is rarely performed for AL amyloidosis (high recurrence in graft from underlying plasma cell dyscrasia) but ATTR cardiac amyloidosis can be considered, especially in young ATTRv patients with severe heart failure. Combined heart-liver transplant historically used for ATTRv but largely supplanted by TTR silencers.

Pearls and Pitfalls

Pearl 1 — Voltage-mass discord beats sparkling

The classic granular sparkling echocardiographic appearance is now considered nonspecific with modern transducers. The single most useful echocardiographic clue is voltage-mass discordance: ECG voltage is inappropriately low for the degree of LV wall thickening on echo. Combined with apical sparing on global longitudinal strain, sensitivity exceeds 85%.

Pitfall 1 — PYP scan before monoclonal workup

Performing PYP scan before excluding AL amyloidosis is the most common diagnostic error. AL can produce false-positive PYP uptake (5–20% of cases), and missing AL leads to delayed life-saving chemotherapy. ALWAYS do SIFE + UIFE + serum free light chain ratio first, regardless of how “obvious” ATTR seems.

Pearl 2 — TTR sequencing is mandatory after every ATTR diagnosis

Even in an 80-year-old male who “obviously” has wild-type ATTR, TTR sequencing should be performed because 5–10% turn out to carry pathogenic variants with implications for relatives. V122I in African ancestry, T60A in Irish ancestry, V30M in Portuguese/Swedish/Japanese — family screening can identify pre-symptomatic carriers eligible for early intervention.

Pitfall 2 — Routine HFrEF medication regimen

Beta-blockers, ACEi/ARB, and digoxin are often poorly tolerated in cardiac amyloidosis and may worsen symptoms. Restrictive physiology with fixed stroke volume needs preserved heart rate for cardiac output; negative inotropy precipitates output failure. Verapamil and diltiazem can cause complete heart block by binding to amyloid fibrils. Diuretics, MRA, SGLT2 inhibitors, and disease-modifying therapy form the core regimen.

Pearl 3 — Anticoagulate even in sinus rhythm

Atrial mechanical dysfunction in cardiac amyloidosis produces thrombus risk independent of AF. Patients with biatrial enlargement and advanced amyloidosis may benefit from anticoagulation even in sinus rhythm. Mandatory TEE before cardioversion regardless of anticoagulation duration — LAA thrombus prevalence is 30% in amyloid AF.

Pitfall 3 — Discontinuing tafamidis too early

Tafamidis benefit emerges at 18 months and continues to grow over years. Patients sometimes stop the drug after 6–12 months of “no improvement” — but the goal is slowing progression, not improvement. Counsel patients that benefit is measured over years and that stable clinical status on tafamidis represents successful therapy.

Pearl 4 — Bilateral carpal tunnel is a key red flag

Bilateral carpal tunnel syndrome can precede cardiac amyloidosis by 5–10 years. Asking about prior carpal tunnel surgery (often forgotten by the patient) in any elderly HFpEF patient adds substantial diagnostic yield. Some centers now recommend amyloid screening in patients undergoing bilateral carpal tunnel release after age 60.

Pitfall 4 — Missing AL in young patients

AL amyloidosis can present at age 40–60 and is rapidly fatal without treatment. Cardiac amyloidosis in any patient under 70, in patients of non-African ancestry, or in patients with proteinuria, neuropathy, periorbital purpura, or macroglossia must be presumed AL until proven otherwise. Same workup applies — but urgency is much greater.

Frequently Asked Questions

When should I screen for cardiac amyloidosis?
Screen any patient over age 60 with HFpEF and LV wall thickness greater than 12 mm, low-flow low-gradient aortic stenosis, unexplained LVH without hypertension history, bilateral carpal tunnel syndrome with cardiac symptoms, lumbar spinal stenosis with HF, or peripheral polyneuropathy with cardiac findings. The diagnostic sequence is monoclonal workup (SIFE + UIFE + serum free light chain ratio) FIRST, then PYP scan if monoclonal workup is negative.
Why must monoclonal workup come before PYP scan?
PYP scintigraphy can be falsely positive in 5–20% of AL amyloidosis cases. AL is far more aggressive than ATTR (median survival 6 months for stage IV without treatment vs 24 months for NAC stage III ATTR), and treating presumed ATTR while missing AL leads to fatal delay in starting chemotherapy. The sequence is: monoclonal workup, then PYP only if monoclonal is fully negative.
What is the Gillmore non-biopsy criteria for ATTR?
All four required: (1) heart failure or cardiac findings consistent with amyloidosis; (2) echocardiographic or CMR findings consistent with amyloidosis; (3) Perugini grade 2 or 3 myocardial uptake on technetium-99m PYP, DPD, or HMDP scan; (4) negative serum and urine immunofixation electrophoresis AND normal serum free light chain ratio. If all four met, specificity for ATTR exceeds 99% and biopsy is not required. Any criterion missing requires endomyocardial or other tissue biopsy with mass spectrometry typing.
How effective is tafamidis?
The ATTR-ACT trial showed a 30% reduction in all-cause mortality (HR 0.70) and 32% reduction in cardiovascular hospitalizations over 30 months. Benefit emerges at approximately 18 months and continues to grow with longer treatment. Open-label extension data confirm survival separation through 60 months. Dose is tafamidis meglumine 61 mg PO once daily. Acoramidis 800 mg BID is an alternative TTR stabilizer with similar mechanism approved in 2024.
Should every ATTR patient have TTR genetic testing?
Yes. Every confirmed ATTR cardiac amyloidosis patient requires TTR gene sequencing because 5–10% of presumed wild-type cases actually carry pathogenic variants with implications for first-degree relatives. Common variants include V122I (3–4% of African ancestry, manifests with cardiomyopathy after age 60), T60A (Irish), and V30M (Portuguese/Swedish/Japanese). Variant disease enables family genetic counseling and consideration of TTR silencer therapy.
Why are beta-blockers and ACE inhibitors poorly tolerated?
Restrictive cardiac amyloidosis has fixed stroke volume — cardiac output depends on preserved heart rate. Beta-blockers blunt this compensatory tachycardia and worsen output. Autonomic neuropathy (especially in AL) causes orthostatic hypotension that is exacerbated by ACEi/ARB and ARNI. Calcium channel blockers verapamil and diltiazem are contraindicated because they bind to amyloid fibrils with high affinity and can precipitate complete heart block. Digoxin similarly binds amyloid and causes toxicity at therapeutic doses. Diuretics, MRA, and SGLT2 inhibitors form the better-tolerated core regimen along with disease-modifying therapy.
When should AL amyloidosis be transplanted?
Autologous stem cell transplantation is reserved for younger fit patients meeting Mayo Clinic criteria: typically age under 70, ECOG performance status 0–2, NT-proBNP under 5000, troponin not severely elevated, eGFR over 30, and absence of severe cardiac involvement. Standard induction is now daratumumab + cyclophosphamide-bortezomib-dexamethasone for 6 cycles regardless of transplant eligibility. The treatment goal is hematologic complete response (negative immunofixation and normal serum free light chain ratio), which predicts cardiac and renal response and is the strongest survival modifier.

When to refer or escalate

Refer to a tertiary amyloidosis center when: PYP scan is equivocal (grade 1) or imaging-clinical findings discordant; monoclonal workup is positive (urgent hematology); ATTR variant identified (genetics + family screening); patient is candidate for TTR silencer or ASCT; aortic stenosis coexists and TAVR is being considered; conduction disease requires device decision; or transplant evaluation is being considered. Multidisciplinary amyloidosis programs (cardiology, hematology, neurology, genetics) substantially improve outcomes through coordinated care.

Leave a Reply

Your email address will not be published. Required fields are marked *